CleveXel develops innovative approaches for the treatment of pathologies with uncovered medical needs.
Capitalizing on a network of scientific experts (L’Institut du Cerveau, Gustave Roussy, Domain Therapeutics, …), we design our programs taking into account recent discoveries on pathophysiological mechanisms. We collaboratewith clinicians and their patients to propose therapeutic solutions that are differentiating because they are also designed to take into account the patients’ life context.
Clevexel develops 4 programs
A1R/A2AR RECEPTOR ANTAGONISTS: CVXL-0069
Specific adenosine receptor antagonists targeting 2 subtypes, at the striatal and cortical level, acting on the memory and arousal disorders that are early and very debilitating symptoms of Parkinson’s disease, , while acting positively on movement control in Parkinson’s patients under dopamine therapy, the current therapeutic arsenal.
TOPICAL FORM OF RADICALS SCAVENGER: CVXL-0095
A local form containing an anti-free radical known to treat oral mucositis and dermatitis induced by radiotherapy, which, unlike other treatments in injectable form, protects patients by reducing the severity of the lesions, without disrupting the cycle of cancer care management in oncology centers.
DUAL INHIBITOR OF SYK & JAK KINASES: CVXL-0255
Dual Syk & Jak3 inhibitors, kinases with a key role in the pathophysiology of immuno-inflammatory diseases (IMID). This dual mechanism of action opens up the possibility by acting both on the progression and on the initiation of the pathology, particularly in dermatitis or asthma.
NEUROPROTECTOR PEPTIDES: CVXL-0301
Modified peptide structures, derived from a viral protein with neuronal tropism, which protect neurons from apoptosis, thus opening a unique opportunity for a treatment acting on the initial mechanisms and capable of relevant medication of the course of neurodegenerative diseases such as Parkinson’s disease, Amyotrophic Lateral Sclerosis or Alzheimer’s disease.